These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 25054578)

  • 21. Heat shock protein vaccines against glioblastoma: from bench to bedside.
    Ampie L; Choy W; Lamano JB; Fakurnejad S; Bloch O; Parsa AT
    J Neurooncol; 2015 Jul; 123(3):441-8. PubMed ID: 26093618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.
    Genoud V; Migliorini D
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunotherapy in brain tumors].
    De Carli E; Delion M; Rousseau A
    Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Clinical Trials and Approaches in the Management of Glioblastoma.
    Valerius AR; Webb LM; Sener U
    Curr Oncol Rep; 2024 May; 26(5):439-465. PubMed ID: 38546941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status of immunotherapy and gene therapy for high-grade gliomas.
    Marsh JC; Goldfarb J; Shafman TD; Diaz AZ
    Cancer Control; 2013 Jan; 20(1):43-8. PubMed ID: 23302906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients.
    Nava S; Lisini D; Pogliani S; Dossena M; Bersano A; Pellegatta S; Parati E; Finocchiaro G; Frigerio S
    Stem Cells Transl Med; 2015 Oct; 4(10):1164-72. PubMed ID: 26273063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.
    Ardon H; Van Gool S; Lopes IS; Maes W; Sciot R; Wilms G; Demaerel P; Bijttebier P; Claes L; Goffin J; Van Calenbergh F; De Vleeschouwer S
    J Neurooncol; 2010 Sep; 99(2):261-72. PubMed ID: 20146084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
    Swartz AM; Li QJ; Sampson JH
    Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current strategies for vaccination in glioblastoma.
    Dutoit V; Migliorini D; Dietrich PY
    Curr Opin Oncol; 2019 Nov; 31(6):514-521. PubMed ID: 31403483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glioblastoma Immune Landscape and the Potential of New Immunotherapies.
    Daubon T; Hemadou A; Romero Garmendia I; Saleh M
    Front Immunol; 2020; 11():585616. PubMed ID: 33154756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
    Erhart F; Buchroithner J; Reitermaier R; Fischhuber K; Klingenbrunner S; Sloma I; Hibsh D; Kozol R; Efroni S; Ricken G; Wöhrer A; Haberler C; Hainfellner J; Krumpl G; Felzmann T; Dohnal AM; Marosi C; Visus C
    Acta Neuropathol Commun; 2018 Dec; 6(1):135. PubMed ID: 30518425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current approaches in glioblastoma multiforme immunotherapy.
    Aghajani M; Jalilzadeh N; Aghebati-Maleki A; Yari A; Tabnak P; Mardi A; Saeedi H; Aghebati-Maleki L; Baradaran B
    Clin Transl Oncol; 2024 Jul; 26(7):1584-1612. PubMed ID: 38512448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial.
    Cho DY; Yang WK; Lee HC; Hsu DM; Lin HL; Lin SZ; Chen CC; Harn HJ; Liu CL; Lee WY; Ho LH
    World Neurosurg; 2012; 77(5-6):736-44. PubMed ID: 22120301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
    Batich KA; Swartz AM; Sampson JH
    Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?
    Van Gool S; De Vleeschouwer S
    Expert Rev Neurother; 2012 Oct; 12(10):1173-6. PubMed ID: 23082731
    [No Abstract]   [Full Text] [Related]  

  • 38. Next-generation vaccines are showing promise against glioblastoma.
    Dillman RO; Bota DA
    Oncotarget; 2024 Aug; 15():543-548. PubMed ID: 39102214
    [No Abstract]   [Full Text] [Related]  

  • 39. [II. Autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma].
    Maruyama T; Muragaki Y; Ishikawa E; Nitta M; Saito T; Ohno T; Iseki H; Okada Y
    Gan To Kagaku Ryoho; 2015 Jun; 42(6):683-6. PubMed ID: 26242005
    [No Abstract]   [Full Text] [Related]  

  • 40. Progress in active-specific immunotherapy of brain malignancies.
    Tjoa BA; Salgaller ML
    Expert Opin Investig Drugs; 2000 Sep; 9(9):2093-101. PubMed ID: 11060795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.